Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies
- PMID: 17116867
- PMCID: PMC1693727
- DOI: 10.1073/pnas.0606304103
Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies
Abstract
The MHC class I-related receptor, neonatal Fc receptor (FcRn), plays a central role in regulating the transport and in vivo persistence of immunoglobulin G (IgG). IgG-FcRn interactions can be targeted for engineering to modulate the in vivo longevity and transport of an antibody, and this has implications for the successful application of therapeutic IgGs. Although mice are widely used to preclinically test antibodies, human and mouse FcRn have significant differences in binding specificity. Here we show that an engineered human IgG1 has disparate properties in murine and human systems. The mutant shows improved transport relative to wild-type human IgG1 in assays of human FcRn function but has short in vivo persistence and competitively inhibits FcRn activity in mice. These studies indicate potential limitations of using mice as preclinical models for the analysis of engineered antibodies. Alternative assays are proposed that serve as indicators of the properties of IgGs in humans.
Conflict of interest statement
Conflict of interest statement: There is a pending patent that describes the mutated human IgG1 used in the studies.
Figures
Similar articles
-
Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.J Drug Target. 2014 May;22(4):269-78. doi: 10.3109/1061186X.2013.875030. Epub 2014 Jan 9. J Drug Target. 2014. PMID: 24404896 Review.
-
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.Nat Biotechnol. 2005 Oct;23(10):1283-8. doi: 10.1038/nbt1143. Epub 2005 Sep 25. Nat Biotechnol. 2005. PMID: 16186811
-
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.MAbs. 2014 Mar-Apr;6(2):422-36. doi: 10.4161/mabs.27854. Epub 2014 Jan 15. MAbs. 2014. PMID: 24492301 Free PMC article.
-
Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.MAbs. 2016 May-Jun;8(4):775-86. doi: 10.1080/19420862.2016.1156285. Epub 2016 Mar 30. MAbs. 2016. PMID: 27030023 Free PMC article.
-
Targeting FcRn for the modulation of antibody dynamics.Mol Immunol. 2015 Oct;67(2 Pt A):131-41. doi: 10.1016/j.molimm.2015.02.007. Epub 2015 Mar 9. Mol Immunol. 2015. PMID: 25766596 Free PMC article. Review.
Cited by
-
Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria.Nat Commun. 2024 Mar 7;15(1):2007. doi: 10.1038/s41467-024-46321-9. Nat Commun. 2024. PMID: 38453922 Free PMC article.
-
Impact of structural modifications of IgG antibodies on effector functions.Front Immunol. 2024 Jan 8;14:1304365. doi: 10.3389/fimmu.2023.1304365. eCollection 2023. Front Immunol. 2024. PMID: 38259472 Free PMC article. Review.
-
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics.MAbs. 2023 Jan-Dec;15(1):2191301. doi: 10.1080/19420862.2023.2191301. MAbs. 2023. PMID: 36998195 Free PMC article. Review.
-
Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates.mBio. 2023 Apr 25;14(2):e0034123. doi: 10.1128/mbio.00341-23. Epub 2023 Mar 22. mBio. 2023. PMID: 36946726 Free PMC article.
-
The therapeutic age of the neonatal Fc receptor.Nat Rev Immunol. 2023 Jul;23(7):415-432. doi: 10.1038/s41577-022-00821-1. Epub 2023 Feb 1. Nat Rev Immunol. 2023. PMID: 36726033 Free PMC article. Review.
References
-
- Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ, Ward ES. Nat Biotechnol. 1997;15:637–640. - PubMed
-
- Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. J Biol Chem. 2001;276:6591–6604. - PubMed
-
- Dall'Acqua W, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. J Immunol. 2002;169:5171–5180. - PubMed
-
- Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vasquez M, et al. J Biol Chem. 2004;279:6213–6216. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials